JP2575604B2 - 沈澱異種蛋白質の精製及び活性化法 - Google Patents
沈澱異種蛋白質の精製及び活性化法Info
- Publication number
- JP2575604B2 JP2575604B2 JP58241820A JP24182083A JP2575604B2 JP 2575604 B2 JP2575604 B2 JP 2575604B2 JP 58241820 A JP58241820 A JP 58241820A JP 24182083 A JP24182083 A JP 24182083A JP 2575604 B2 JP2575604 B2 JP 2575604B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- solution
- refractor
- denaturing
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 325
- 102000004169 proteins and genes Human genes 0.000 title claims description 318
- 238000000034 method Methods 0.000 title claims description 151
- 238000000746 purification Methods 0.000 title description 37
- 230000004913 activation Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims description 154
- 239000000243 solution Substances 0.000 claims description 123
- 239000008188 pellet Substances 0.000 claims description 68
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 38
- 239000004202 carbamide Substances 0.000 claims description 38
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical group OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 36
- -1 sulfhydryl compound Chemical class 0.000 claims description 23
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 15
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 10
- 108010024636 Glutathione Proteins 0.000 claims description 9
- 238000000464 low-speed centrifugation Methods 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 239000002808 molecular sieve Substances 0.000 claims description 8
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 8
- 239000007800 oxidant agent Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000003599 detergent Substances 0.000 claims description 6
- 150000002357 guanidines Chemical class 0.000 claims description 6
- 210000002421 cell wall Anatomy 0.000 claims description 5
- 230000022534 cell killing Effects 0.000 claims description 3
- 239000003495 polar organic solvent Substances 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 306
- 239000000872 buffer Substances 0.000 description 64
- 239000003398 denaturant Substances 0.000 description 53
- 239000000725 suspension Substances 0.000 description 41
- 108010000521 Human Growth Hormone Proteins 0.000 description 32
- 102000002265 Human Growth Hormone Human genes 0.000 description 31
- 239000000854 Human Growth Hormone Substances 0.000 description 31
- 239000002245 particle Substances 0.000 description 30
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 239000006228 supernatant Substances 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 24
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 24
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 23
- 239000003638 chemical reducing agent Substances 0.000 description 23
- 239000002609 medium Substances 0.000 description 22
- 239000007983 Tris buffer Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 20
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 19
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 18
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 18
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- 229960000789 guanidine hydrochloride Drugs 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 229960005356 urokinase Drugs 0.000 description 17
- 238000005119 centrifugation Methods 0.000 description 16
- 238000005342 ion exchange Methods 0.000 description 15
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- 241001646716 Escherichia coli K-12 Species 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 108090000467 Interferon-beta Proteins 0.000 description 11
- 108020004511 Recombinant DNA Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000000502 dialysis Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 102000003996 Interferon-beta Human genes 0.000 description 10
- 229960004198 guanidine Drugs 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 9
- 108010006025 bovine growth hormone Proteins 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000003127 radioimmunoassay Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 description 9
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 229960000187 tissue plasminogen activator Drugs 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000000527 sonication Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000018997 Growth Hormone Human genes 0.000 description 6
- 108010051696 Growth Hormone Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000000122 growth hormone Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000006176 redox buffer Substances 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- HAEPBEMBOAIUPN-UHFFFAOYSA-L sodium tetrathionate Chemical compound O.O.[Na+].[Na+].[O-]S(=O)(=O)SSS([O-])(=O)=O HAEPBEMBOAIUPN-UHFFFAOYSA-L 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108090000565 Capsid Proteins Proteins 0.000 description 5
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 5
- 108010053070 Glutathione Disulfide Proteins 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000012506 Sephacryl® Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 238000000703 high-speed centrifugation Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 238000001742 protein purification Methods 0.000 description 5
- 230000007420 reactivation Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 108010064037 prorennin Proteins 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 206010037742 Rabies Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003196 chaotropic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 125000002228 disulfide group Chemical group 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 3
- 238000006277 sulfonation reaction Methods 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108090000746 Chymosin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- SXOUIMVOMIGLHO-AATRIKPKSA-N (E)-3-(indol-2-yl)acrylic acid Chemical compound C1=CC=C2NC(/C=C/C(=O)O)=CC2=C1 SXOUIMVOMIGLHO-AATRIKPKSA-N 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000617590 Escherichia coli K1 Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101800001442 Peptide pr Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710150593 Protein beta Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000013542 high molecular weight contaminant Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
- C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45218782A | 1982-12-22 | 1982-12-22 | |
| US45234482A | 1982-12-22 | 1982-12-22 | |
| US45235582A | 1982-12-22 | 1982-12-22 | |
| US45235782A | 1982-12-22 | 1982-12-22 | |
| US45225382A | 1982-12-22 | 1982-12-22 | |
| US45235682A | 1982-12-22 | 1982-12-22 | |
| US45236382A | 1982-12-22 | 1982-12-22 | |
| US45225282A | 1982-12-22 | 1982-12-22 | |
| US452252 | 1982-12-22 | ||
| US452187 | 1982-12-22 | ||
| US452344 | 1982-12-22 | ||
| US452253 | 1982-12-22 | ||
| US452357 | 1982-12-22 | ||
| US452363 | 1982-12-22 | ||
| US452355 | 2003-06-02 | ||
| US452356 | 2003-06-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59161321A JPS59161321A (ja) | 1984-09-12 |
| JP2575604B2 true JP2575604B2 (ja) | 1997-01-29 |
Family
ID=27575443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58241820A Expired - Lifetime JP2575604B2 (ja) | 1982-12-22 | 1983-12-21 | 沈澱異種蛋白質の精製及び活性化法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0114506B1 (en, 2012) |
| JP (1) | JP2575604B2 (en, 2012) |
| AU (1) | AU568109B2 (en, 2012) |
| BR (1) | BR8307086A (en, 2012) |
| CA (1) | CA1219234A (en, 2012) |
| DE (1) | DE3380850D1 (en, 2012) |
| GR (1) | GR79124B (en, 2012) |
| HU (1) | HU197357B (en, 2012) |
| IL (1) | IL70474A (en, 2012) |
| MX (1) | MX166885B (en, 2012) |
| NZ (1) | NZ206615A (en, 2012) |
| PT (1) | PT77866B (en, 2012) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| US4476049A (en) * | 1983-09-20 | 1984-10-09 | Hoffmann-La Roche Inc. | Method for the extraction of immune interferon |
| JPH064680B2 (ja) * | 1985-01-09 | 1994-01-19 | 武田薬品工業株式会社 | 高濃度ヒトγ型インターフェロンフラグメント水溶液の製造法 |
| JPS60155137A (ja) * | 1984-01-23 | 1985-08-15 | Takeda Chem Ind Ltd | 高濃度ヒトγ型インタ−フエロン水溶液の製造法 |
| US4530787A (en) * | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| JPS60258129A (ja) * | 1984-06-05 | 1985-12-20 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの活性化法 |
| ATE64956T1 (de) * | 1984-06-14 | 1991-07-15 | Ciba Geigy Ag | Verfahren zur herstellung von thrombininhibitoren. |
| CA1267615A (en) * | 1984-08-27 | 1990-04-10 | Dan Hadary | Method for recovering purified growth hormones from genetically engineered microorganisms |
| US5871956A (en) * | 1984-12-06 | 1999-02-16 | Amgen Inc. | Recombinant methods for production of serine inhibitors and DNA sequences useful for same |
| US6291662B1 (en) | 1984-12-05 | 2001-09-18 | Amgen Inc. | Recombinant methods for production of serine protease inhibitors and DNA sequences |
| US6132990A (en) * | 1984-12-06 | 2000-10-17 | Amgen Boulder Inc. | Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same |
| IL95223A (en) * | 1984-12-06 | 1992-08-18 | Synergen Biolog Inc | Dna sequence for production of serine protease inhibitors |
| US5900400A (en) * | 1984-12-06 | 1999-05-04 | Amgen Inc. | Serine protease inhibitor analogs |
| WO1986004608A1 (en) * | 1985-02-05 | 1986-08-14 | Synergen Biologicals, Inc. | Metalloproteinase inhibitor sequence recombinant vector system for using same and recombinant-dna method for the manufacture of same |
| US4731440A (en) * | 1985-02-22 | 1988-03-15 | Monsanto Company | Method of somatotropin solubilization using dimethylsulfone and naturation |
| US4861868A (en) | 1985-02-22 | 1989-08-29 | Monsanto Company | Production of proteins in procaryotes |
| ES8800957A1 (es) * | 1985-02-22 | 1987-12-01 | Monsanto Co | Un metodo para la solubilizacion y renaturalizacion de proteina somatotropina |
| US4652630A (en) * | 1985-02-22 | 1987-03-24 | Monsanto Company | Method of somatotropin naturation |
| US6084073A (en) * | 1985-03-25 | 2000-07-04 | Chiron Corporation | Recombinant ricin toxin |
| FR2579223B1 (fr) * | 1985-03-25 | 1988-12-09 | Genetica | Procede de preparation microbiologique de la serum-albumine humaine |
| DE3511011A1 (de) * | 1985-03-27 | 1986-10-02 | Hoechst Ag, 6230 Frankfurt | Verfahren zur isolierung und reinigung von (alpha)-interferonen |
| GB8508340D0 (en) * | 1985-03-29 | 1985-05-09 | Creighton T E | Production of protein |
| DE3683186D1 (de) | 1985-04-25 | 1992-02-13 | Hoffmann La Roche | Rekombinantes humaninterleukin-1. |
| JPH0640832B2 (ja) * | 1985-05-10 | 1994-06-01 | 味の素株式会社 | インタ−ロイキン２ポリペプチドの回収方法 |
| EP0226639B1 (en) * | 1985-05-29 | 1990-11-14 | The Green Cross Corporation | Process for preparing heterogenic protein |
| US5248769A (en) * | 1985-06-26 | 1993-09-28 | Cetus Oncology Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| EP0229110B1 (en) | 1985-06-26 | 1992-05-20 | The Upjohn Company | Solubilization and oxidation of somatotropin from transformed microorganisms |
| US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| US4766224A (en) * | 1985-08-19 | 1988-08-23 | International Minerals & Chemical Corp. | Purification and activation of proteins from insoluble inclusion bodies |
| US4656255A (en) * | 1985-09-09 | 1987-04-07 | International Minerals & Chemical Corp. | Protein recovery |
| DE3537708A1 (de) * | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
| US5453363A (en) * | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
| US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
| US5831022A (en) * | 1986-02-18 | 1998-11-03 | Hoffmann-La Roche Inc. | Purification of recombinant human IL-1α |
| FR2594846B1 (fr) * | 1986-02-21 | 1989-10-20 | Genetica | Procede de preparation de la serum albumine humaine mature |
| US4689401A (en) * | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| DE3611817A1 (de) * | 1986-04-08 | 1987-10-15 | Boehringer Mannheim Gmbh | Verfahren zur renaturierung von proteinen |
| US4705848A (en) * | 1986-06-02 | 1987-11-10 | International Minerals & Chemical Corp. | Isolation of bioactive, monomeric growth hormone |
| DE3618817A1 (de) * | 1986-06-04 | 1987-12-10 | Behringwerke Ag | Verfahren zur gewinnung aktiver proteine aus einer biologisch inaktiven form |
| US4801686A (en) * | 1986-09-04 | 1989-01-31 | Immunex Corporation | Purification of recombinant interleukin-1 |
| US5179199A (en) * | 1986-10-20 | 1993-01-12 | Genzyme Corporation | Protein purification |
| AU612133B2 (en) * | 1987-02-20 | 1991-07-04 | Natinco Nv | Production of proteins in active forms |
| US5026828A (en) * | 1987-02-27 | 1991-06-25 | Merck & Co., Inc. | Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast |
| IL86090A (en) * | 1987-04-16 | 1993-03-15 | Cetus Oncology Corp | Production of purified, biologically active, bacterially produced recombinant human csf-1 |
| US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| CA1339757C (en) | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
| WO1988008428A1 (en) * | 1987-04-28 | 1988-11-03 | Amgen Inc. | Method for purifying granulocyte/macrophage colony stimulating factor |
| US5162507A (en) * | 1987-05-11 | 1992-11-10 | Cetus Corporation | Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms |
| WO1988008849A1 (en) * | 1987-05-11 | 1988-11-17 | Cetus Corporation | Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms |
| US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| JP2669859B2 (ja) * | 1987-08-04 | 1997-10-29 | 協和醗酵工業株式会社 | タンパク質の再活性化法 |
| US4985544A (en) * | 1987-08-04 | 1991-01-15 | Kyowa Hakko Kogyo Co., Ltd. | Process for renaturing fish growth hormone |
| US5011915A (en) * | 1987-10-26 | 1991-04-30 | Merck & Co., Inc. | Process for purifying recombinant hepatitis antigens |
| EP0325691B1 (de) * | 1988-01-25 | 1993-04-07 | Consortium für elektrochemische Industrie GmbH | Verfahren zur Solubilisierung von unlöslichem Protein |
| JPH01257491A (ja) * | 1988-04-08 | 1989-10-13 | Tosoh Corp | 不溶性融合異種蛋白質の処理方法 |
| US4999422A (en) * | 1988-04-15 | 1991-03-12 | Biogen, N.V. | Continuous method of refolding proteins |
| JP2812760B2 (ja) * | 1988-05-31 | 1998-10-22 | カイロン コーポレイション | 微生物宿主から異種蛋白質を含有する屈折体を回収する方法 |
| US5089473A (en) | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
| CA1340586C (en) * | 1988-09-23 | 1999-06-08 | Cetus Corporation | Process for recovering microbially produced interferon-beta |
| DE3832898A1 (de) * | 1988-09-28 | 1990-04-12 | Boehringer Mannheim Gmbh | Praeparat von in prokaryonten exprimiertem plasminogenaktivator |
| DE3835350A1 (de) * | 1988-10-17 | 1990-04-19 | Boehringer Mannheim Gmbh | Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern |
| US5179196A (en) * | 1989-05-04 | 1993-01-12 | Sri International | Purification of proteins employing ctap-iii fusions |
| GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| DE4039415A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Mannheim Gmbh | Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest |
| US5023323A (en) * | 1990-09-12 | 1991-06-11 | Monsanto Company | Method of somatotropin naturation |
| JPH04113933U (ja) * | 1991-03-22 | 1992-10-06 | 富泰 本多 | 化粧板 |
| JPH084290Y2 (ja) * | 1991-03-22 | 1996-02-07 | 富泰 本多 | 化粧板 |
| US6869925B1 (en) * | 1992-09-09 | 2005-03-22 | Amgen Inc. | Inhibition of retrovirus infection |
| US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| US6017880A (en) * | 1994-03-09 | 2000-01-25 | Amgen Inc. | Inhibition of retrovirus infection |
| US5437986A (en) * | 1994-06-22 | 1995-08-01 | Schering Corporation | Extraction of heterologous insoluble proteins from bacteria |
| FI970230L (fi) * | 1994-07-25 | 1997-01-20 | Ciba Geigy Ag | Menetelmä proteiinien, kuten yhdistelmä-DNA-hirudiinin tai -epidermaalisen kasvutekijän laskostamiseksi |
| TW517059B (en) | 1994-07-25 | 2003-01-11 | Ciba Geigy Ag | New process for the production of biologically active protein |
| US6037145A (en) * | 1994-09-07 | 2000-03-14 | Suntory Limited | Process for production of protein |
| GB9425138D0 (en) | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
| EP0904355B1 (de) * | 1996-06-11 | 2004-03-03 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von denaturiertem protein |
| US5914390A (en) * | 1997-05-12 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Methods for increasing yields of recombinant proteins |
| WO1999010483A2 (de) * | 1997-08-22 | 1999-03-04 | Roche Diagnostics Gmbh | Autokatalytisch aktivierbare vorstufen von proteasen und deren verwendung |
| JP3734634B2 (ja) | 1999-03-03 | 2006-01-11 | ヒゲタ醤油株式会社 | タンパク質の活性化方法及び該装置 |
| IN187900B (en, 2012) * | 2000-02-01 | 2002-07-20 | Torrent Pharmaceuticals Ltd | |
| KR100409092B1 (ko) * | 2000-12-22 | 2003-12-11 | 주)녹십자 | 단백질의 제조 방법 |
| KR101099398B1 (ko) | 2003-09-30 | 2011-12-27 | 아스비오파마 가부시키가이샤 | ＯｍｐＴ 프로테아제 변이체를 이용한 폴리펩티드의 절단 방법 |
| EP1910415A4 (en) * | 2005-07-25 | 2010-08-11 | Trubion Pharmaceuticals Inc | COMPOSITIONS AND PROCESSES FOR PROTEIN DEGREGATION |
| EP2547699B1 (en) | 2010-03-17 | 2016-10-19 | ratiopharm GmbH | Method for obtaining biologically active recombinant human g-csf |
| JP5805943B2 (ja) * | 2010-12-08 | 2015-11-10 | 株式会社北里大塚バイオメディカルアッセイ研究所 | 百日咳菌のＦｉｍ３の製造方法、及び、百日咳の検出方法 |
| USD1086051S1 (en) * | 2022-09-30 | 2025-07-29 | Maxcyte, Inc. | Electroporation gasket |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4350764A (en) * | 1980-03-10 | 1982-09-21 | The Regents Of The University Of California | Microbiological synthesis of beta endorphin |
| AU564690B2 (en) * | 1980-04-03 | 1987-08-20 | Biogen Idec Ma Inc. | Process for producing human fibroblast interferon-like polypeptides using recombinant dna |
| IL63916A0 (en) * | 1980-09-25 | 1981-12-31 | Genentech Inc | Microbial production of human fibroblast interferon |
| AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| JPS58157800A (ja) * | 1982-03-16 | 1983-09-19 | Sankyo Co Ltd | プラスミドｐｓａｎ１８１ |
-
1983
- 1983-12-16 GR GR73270A patent/GR79124B/el unknown
- 1983-12-18 IL IL70474A patent/IL70474A/xx not_active IP Right Cessation
- 1983-12-19 NZ NZ206615A patent/NZ206615A/en unknown
- 1983-12-20 AU AU22594/83A patent/AU568109B2/en not_active Expired
- 1983-12-21 HU HU834379A patent/HU197357B/hu unknown
- 1983-12-21 JP JP58241820A patent/JP2575604B2/ja not_active Expired - Lifetime
- 1983-12-21 EP EP83307840A patent/EP0114506B1/en not_active Expired
- 1983-12-21 CA CA000443903A patent/CA1219234A/en not_active Expired
- 1983-12-21 MX MX199852A patent/MX166885B/es unknown
- 1983-12-21 PT PT77866A patent/PT77866B/pt unknown
- 1983-12-21 DE DE8383307840T patent/DE3380850D1/de not_active Expired
- 1983-12-22 BR BR8307086A patent/BR8307086A/pt unknown
Non-Patent Citations (3)
| Title |
|---|
| Ｂｉｏｃｈｅｍｉｓｔｒｙ，９［２５］Ｐ．５０１５−５０２２３ |
| Ｊ．Ｂｉｏｌ，Ｃｈｅｍ，２５０［２１］Ｐ．８４７７−８４８２ |
| Ｊ．Ｂｉｏｌ，Ｃｈｅｍ，２５３［１０］（１９７８）Ｐ．３４５３−３４５８ |
Also Published As
| Publication number | Publication date |
|---|---|
| IL70474A0 (en) | 1984-03-30 |
| NZ206615A (en) | 1988-03-30 |
| PT77866B (en) | 1986-04-09 |
| MX166885B (es) | 1993-02-10 |
| CA1219234A (en) | 1987-03-17 |
| EP0114506B1 (en) | 1989-11-15 |
| BR8307086A (pt) | 1985-02-12 |
| AU2259483A (en) | 1984-06-28 |
| GR79124B (en, 2012) | 1984-10-02 |
| AU568109B2 (en) | 1987-12-17 |
| HU197357B (en) | 1989-03-28 |
| EP0114506A1 (en) | 1984-08-01 |
| JPS59161321A (ja) | 1984-09-12 |
| DE3380850D1 (en) | 1989-12-21 |
| IL70474A (en) | 1989-09-28 |
| PT77866A (en) | 1984-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2575604B2 (ja) | 沈澱異種蛋白質の精製及び活性化法 | |
| US4512922A (en) | Purification and activity assurance of precipitated heterologous proteins | |
| US4620948A (en) | Purification and activity assurance of precipitated heterologous proteins | |
| US4511502A (en) | Purification and activity assurance of precipitated heterologous proteins | |
| US4518526A (en) | Purification and activity assurance of precipitated heterologous proteins | |
| US4511503A (en) | Purification and activity assurance of precipitated heterologous proteins | |
| US4599197A (en) | Purification and activity assurance of precipitated heterologous proteins | |
| US4766224A (en) | Purification and activation of proteins from insoluble inclusion bodies | |
| EP0279619B1 (en) | Production of proteins in active forms | |
| EP0215625B1 (en) | Protein recovery | |
| JPH06102034B2 (ja) | タンパク質の生産方法 | |
| NO863424L (no) | Fremgangsmaate for rensing av et interferon. | |
| JP2006517415A5 (en, 2012) | ||
| IE66334B1 (en) | Production of proteins in active forms | |
| JPH01257491A (ja) | 不溶性融合異種蛋白質の処理方法 | |
| HUP0002573A2 (hu) | Eljárás csont eredetű faktor tisztított dimerjének előállítására | |
| PT81012B (pt) | Processo para a recuperacao de hormonas de crescimento purificadas a partir de microrganismos tratados por engenharia genetica | |
| JP2517100B2 (ja) | ヒト顆粒球コロニ―刺激因子活性を有する蛋白質の精製法 | |
| JP3930051B2 (ja) | 正しく折畳まれた生物学的に活性の組換えタンパク質の製造方法 | |
| IE56376B1 (en) | Methods of purification and reactivation of precipitated heterologous proteins | |
| RU2123010C1 (ru) | Способ получения рекомбинантного интерферона-альфа-2 из нерастворимых тел включения | |
| Lutsenko et al. | Development of the method of isolation and purification of the recombinant human interleukin-7 | |
| CN114891109A (zh) | 一种用于曲妥珠单链抗体及与其序列同源的单链抗体的变复性方法 | |
| JPH02227076A (ja) | 遺伝子組換え菌で製造された不溶性蛋白質の活性化法 | |
| JPH04320693A (ja) | タンパクの精製方法 |